ACC pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
20 of 25 arms with a reported figure. Choose arms to narrow the chart.
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source). objective response rate: 35.6%, ASCO 2026
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source). objective response rate: 46.9%, ASCO 2026; post hoc
REM-422 24 mg. objective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)
Lenvatinib (off Label) 24 mg. objective response rate: 15.6%, primary analysis
Lenvatinib (off Label) 24 mg. objective response rate: 11.5%, primary analysis
Lenvatinib (off Label) not stated in source. objective response rate: 6%, ASCO 2023 (search record)
Axitinib (off Label) 5 mg. objective response rate: 0%, primary analysis
Axitinib (off Label) axitinib 5 mg twice daily + avelumab. confirmed objective response rate: 18%, primary analysis
Rivoceranib 700 mg. objective response rate (investigator): 15.3%, primary analysis
Rivoceranib 700 mg. objective response rate (independent review): 9.7%, primary analysis
Counts, not percents 5
- RGT-61159 at or below RP2D (mixed doses). partial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending
- Osugacestat (AL101, BMS-906024) 4 mg. responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024
- Osugacestat (AL101, BMS-906024) 6 mg. responders (CR or PR): 2 patients (of 42), final
- Amivantamab not stated in source. responders: 1 patients (of 21), results posted 05.08.2026
- Regorafenib (off Label) not stated in source. responders (CR or PR): 1 patients (of 38), results posted 09.10.2025
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.